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Abstract: Mixed dyslipidemia, characterized by a lipid triad of elevated triglycerides (TG), 
elevated low-density lipoprotein-cholesterol (LDL-C) and reduced high-density lipoprotein-
cholesterol (HDL-C), is a common and frequently difficult to manage condition. The use of 
combination medications is often needed to effectively treat the lipid triad. The co-administration 
of statins and fibrates may provide the desired endpoints but safety issues such as toxicity to the 
muscles, liver and kidneys are a concern. Given the potency of rosuvastatin to lower LDL-C and 
fenofibrate’s effectiveness in lowering TG, the use of this specific combination may be desirable 
in treating mixed dyslipidemia. Pharmacokinetic studies revealed no significant interactions with 
the concomitant use of rosuvastatin and fenofibrate or its active metabolite fenofibric acid. Clini-
cal studies evaluating the efficacy and safety of this combination therapy demonstrate significant 
reductions in TG and LDL-C levels, and elevations in HDL-C. Safety data from clinical trials 
reveal no major adverse reactions. However, case reports of adverse events have been published 
and monitoring for potential adverse reactions of the individual agents is advised. Overall, current 
data suggest the combination of rosuvastatin and fenofibrate or fenofibric acid is a safe combina-
tion to utilize when managing difficult to treat mixed dyslipidemia patients.
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Introduction
Mixed or atherogenic dyslipidemia is characterized by a lipid triad of elevated triglyc-
erides (TG), elevated low-density lipoprotein-cholesterol (LDL-C) and reduced high-
density lipoprotein-cholesterol (HDL-C).1,2 A high prevalence of mixed dyslipidemia 
occurs because many patients present with common risk factors such as obesity, diabetes 
mellitus or insulin resistance, metabolic syndrome and physical inactivity. A higher 
risk of coronary heart disease (CHD) has been associated with mixed dyslipidemia.
The National Cholesterol Education Program, Adult Treatment Panel III (NCEP 
ATP III) emphasizes the need for weight reduction and increased physical activity in 
the management of mixed dyslipidemia.1,2 The use of medications to treat the lipid 
triad may necessitate the use of combination therapy. The 3-hydroxy-3-methylglutaryl 
coenzyme A reductase inhibitors (HMG-CoA reductase inhibitors or statins) have a 
primary effect of lowering LDL-C with a modest effect on lowering TG and raising 
HDL-C.3,4 To further lower TG and increase HDL-C, other pharmacologic agents are 
used such as a fibrate (fenofibrate, clofibrate, gemfibrozil, fenofibric acid) or niacin.5–7 
The co-administration of statins and fibrates may provide a positive effect on the lipid 
triad but safety issues such as toxicity to the muscles, liver and kidneys are a concern.8,9 
The newest statin to enter the market is rosuvastatin.10–12 Rosuvastatin reduces LDL-C Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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by 45%–63% with doses of 5–20 mg per day, which is a 
greater mean reduction compared to equivalent doses of other 
statins. Given the potency of rosuvastatin to lower LDL-C 
and fenofibrate’s effectiveness in lowering TG, the use of this 
combination may be desirable in treating mixed dyslipidemia 
patients. A new fibrate, fenofibric acid, is available for treat-
ing mixed dyslipidemia to lower TG and increase HDL-C in 
patients already receiving optimal statin doses.9,13 Medical 
literature was reviewed to support the use of this newer drug 
combination. This article will evaluate the efficacy and safety 
of the concomitant use of rosuvastatin with fenofibrate or 
fenofibric acid for mixed dyslipidemia.
Data sources
A literature search was conducted using the terms rosuvas-
tatin, fenofibrate, fenofibric acid, and ABT-335. MEDLINE, 
BIOSIS, EBSCOhost, and OVID databases were primary 
search sites from 1991 to January 2010. All English-based 
articles and abstracts obtained from the literature searches 
were reviewed. Additional information was obtained from 
references cited in the articles.
Rationale to use rosuvastatin 
and fenofibrate/fenofibric acid 
combination
Rosuvastatin works similar to other statins by inhibiting 
HMG-CoA reductase.14 The inhibition of this enzyme 
increases the number of LDL-C receptors on hepatocytes, 
thus facilitating the removal of LDL-C from the plasma. Other 
positive effects on lipid parameters include plasma reductions 
in total cholesterol (TC), apolipoprotein B (ApoB), TG, and 
an increase in HDL-C (Table 1).15 The effect of rosuvastatin 
on these parameters is more pronounced compared to other 
statins therefore it may be advantageous to utilize this agent to 
reach desired treatment goals in difficult to treat patients.14
Fenofibrate is rapidly metabolized by esterases to its 
active form of fenofibric acid.16 Both fenofibrate and feno-
fibric acid are available commercially and are primarily 
utilized for lowering TG and raising HDL-C through acti-
vating the peroxisome proliferator-activated receptor alpha 
(PPAR-alpha).9 This receptor is expressed in a variety of 
tissues and results in the breakdown of lipids and removal of 
TG from the plasma. The increase in PPAR-alpha   activation 
also results in the facilitation of LDL-C removal from the 
plasma, a decrease in ApoB, and an increase in HDL-C 
through the stimulation of apolipoprotein A-I (ApoA-I) and 
apolipoprotein (ApoA-II) synthesis. The effects of fenofi-
brate and fenofibric acid monotherapy on lipid parameters 
are summarized in Table 1.16,17 The effect on the lipid profile 
will vary and may depend on the baseline lipid profile and 
lipid phenotype.13 A more dramatic increase in HDL-C 
occurs when initial HDL-C levels are less than 40 mg/dL. 
Lowering of TG may range from 20%–50% with the great-
est reductions seen in patients with baseline TG greater than 
500 mg/dL.13,16 While LDL-C reductions up to 20% may 
occur, typical lowering is usually much less. Fibrates may 
actually increase LDL-C in subjects with TG greater than 300 
mg/dL, therefore they are not typically used for additional 
LDL-C lowering.13,18 The overall effects of fenofibrate on 
lipid parameters compliment the positive effects seen with 
rosuvastatin therapy.9
The major individual pharmacokinetic properties of feno-
fibrate, fenofibric acid and rosuvastatin are summarized in 
Table 2.15–17 Pharmacokinetic interaction studies have been 
conducted evaluating the use of fibrates with rosuvastatin. 
Gemfibrozil has been shown to have a significant pharma-
cokinetic interaction with rosuvastatin as the concentrations 
of rosuvastatin were approximately doubled.19 This interac-
tion leads to concern for potential toxicities (ie, myopathy) 
related to the combination therapy of fibrates and rosuvasta-
tin. A study by Prueksaritanont et al evaluated the metabolism 
of fibrates and statins when used together and suggests that 
all fibrates may not be the same in regards to interacting with 
statins.20 While gemfibrozil appears to have a significant 
impact on the metabolism pathway of rosuvastatin, fenofi-
brate appears to lack a significant interaction.
Pharmacokinetic studies evaluating the concomitant use 
of fenofibrate or fenofibric acid plus rosuvastatin have been 
conducted. A 3-way crossover study by Martin et al evaluated 
the pharmacokinetics of rosuvastatin 10 mg daily and 
fenofibrate 67 mg 3 times daily.21 Fourteen healthy   Caucasian 
males were given each agent alone or in combination for 
7 days. A 3-week washout period was required between 
treatments. Assessment after 1 week revealed a 7% increase 
Table 1 Mean percent changes in lipid parameters in patients 
with hyperlipidemia and mixed dyslipidemia15–17
Rosuvastatin Fenofibratea Fenofibric 
acid
Dose 5 mg 10 mg 20 mg 40 mg 145 mg 135 mg
TC –33 –36 –40 –46 –18.7 –12.4
LDL-C –45 –52 –55 –63 –20.6 –5.1
TG –35 –10 –23 –28 –28.9 –31
HDL-C 13 14 8 10 11 16.3
ApoB –38 –42 –46 –54 –25.1 –15.6
Note: aPooled cohort.
Abbreviations: TC, total cholesterol; LDL-C, low density lipoprotein-cholesterol; TG, 
triglycerides; HDL-C, high-density lipoprotein-cholesterol; ApoB, apolipoprotein B.Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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in the area under the curve (AUC) of   rosuvastatin when given 
with fenofibrate versus rosuvastatin alone. A 21% increase 
in the maximum concentration (Cmax) of rosuvastatin was 
seen when given with fenofibrate compared to rosuvastatin 
alone. Both of these increases were not statistically signifi-
cant. The Cmax and AUC of fenofibrate were not affected 
by concomitant rosuvastatin therapy. This data suggests no 
clinically significant pharmacokinetic interaction exists 
between rosuvastatin and fenofibrate. However it should be 
noted that the population was limited to healthy, Caucasian 
males, and higher doses of rosuvastatin were not evaluated.
The pharmacokinetics of concomitant fenofibric acid and 
rosuvastatin were evaluated by Zhu et al in a 3-period cross-
over trial.22 Sixteen men and 2 women were given rosuvastatin 
40 mg, fenofibric acid 135 mg, or the combination for ten days. 
A 2-week washout period occurred between treatments. Results 
of this study revealed rosuvastatin had no effect on the half-life, 
time to maximum concentration (Tmax), Cmax, minimum 
concentration (Cmin), AUC or oral clearance of fenofibric 
acid. Analysis of rosuvastatin pharmacokinetics demonstrated 
fenofibric acid had no effect on the half-life, Tmax, Cmin, 
AUC, and oral clearance of   rosuvastatin. A 19.6% increase in 
rosuvastatin Cmax occurred when fenofibric acid was given in 
combination versus rosuvastatin alone. The authors proposed 
this effect may be attributed to the mild to moderate inhibition 
of fenofibric acid on CYP450 2C9, but determined that the 
small increase was not likely to have clinical implications.
Studies evaluating the combination 
of rosuvastatin and fenofibrate
Durrington et al studied the effect of fenofibrate alone or 
in combination with rosuvastatin in type 2 diabetics with 
elevated TG and TC.23 Patients included in the multicenter 
study were men and women with type 2 diabetes at least 
18 years of age with a TG range of $200 to ,800 mg/dL, 
TC $ 200 mg/dL, hemoglobin A1c (HBA1c) , 10%, and 
compliance with the National Cholesterol Education Program 
(NCEP) step I diet. A total of 216 patients were enrolled in 
the study. After 6 weeks of the NCEP diet, patients were 
randomized to a 6-week fixed dose phase of rosuvastatin 
5 mg, rosuvastatin 10 mg, or placebo (divided into 2 groups). 
This was followed by an 18-week dose-titration period with 
options of increasing the rosuvastatin dose, adding fenofi-
brate, or receiving fenofibrate alone (Table 3). Patients could 
then move to the next dose level every 6 weeks if the LDL-C 
was greater than 50 mg/dL. Endpoint assessment, at 6 and 
24 weeks, were TG, TC, LDL-C, HDL-C, VLDL, apolipopro-
tein (Apo) A-I, ApoB,   LDL-C:HDL-C ratio, TC:HDL-C ratio, 
Table 2 Pharmacokinetic properties15–17
Rosuvastatin Fenofibrate Fenofibric acid
Half-life 19 hours 20 hours 20 hours
Metabolism ∼10% via CYP450 2C9 Rapidly hydrolyzed to fenofibric acid Conjugation via glucuronic acid 
elimination ∼90% fecal  60% urine, 25% fecal Primarily urine
Renal impairment Dose adjust if CrCl , 30 mL/min Dose adjust if CrCl 30–80 ml/min  
Avoid if CrCl , 30 mL/min
Dose adjust if CrCl 30–80 mL/min   
Avoid if CrCl , 30 mL/min
Hepatic impairment Avoid in active liver disease No data No data
Abbreviation: CrCl, creatinine clearance.
Table 3 Treatment groups in the Durrington study23
Fixed-Dose Phase week 6  Placebo Rosuvastatin 5 mg Rosuvastatin 10 mg Placebo 
Dose-Titration Phase 
week 12
Rosuvastatin  
10 mg
Rosuvastatin 5 mg  
Plus  
Fenofibrate 67 mg  
every day
Rosuvastatin 10 mg  
Plus  
Fenofibrate 67 mg 
every day
Fenofibrate 67 mg 
every day
Dose-Titration Phasea 
week 18
Rosuvastatin  
20 mg
Rosuvastatin 5 mg  
Plus  
Fenofibrate 67 mg  
twice a day
Rosuvastatin 10 mg 
Plus  
Fenofibrate 67 mg  
twice a day
Fenofibrate 67 mg   
twice a day
Dose-Titration Phasea 
week 24 
Rosuvastatin  
40 mg
Rosuvastatin 5 mg  
Plus  
Fenofibrate 67 mg  
three times a day
Rosuvastatin 10 mg 
Plus  
Fenofibrate 67 mg  
three times a day
Fenofibrate 67mg  
three times a day
Notes: aDose of rosuvastatin or fenofibrate monotherapy groups titrated upward if LDL-C . 50 mg/dL.Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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non-HDL-C:HDL-C ratio, and ApoB:Apo A-I ratio. Table 4 
summarizes the outcomes. At week 24, the percentage of 
patients achieving the LDL-C goal of ,100 mg/dL was 86% 
with   rosuvastatin 40 mg (n = 50), 75.5% with   rosuvastatin 
10 mg plus   fenofibrate 67 mg 3 times a day (n = 53), 75% 
with rosuvastatin 5 mg plus fenofibrate 67 mg 3 times a 
day (n = 60) and 4.1% with fenofibrate 67 mg 3 times a day 
(n = 49). Treatment-related adverse effects in the rosuvastatin 
Table 4 Lipid outcomes in the Durrington study at 6 and 24 weeks23
Placeboa then 
rosuvastatin 
10/20/40 mg  
n = 51
Rosuvastatin 5 mg plus 
fenofibrate group  
n = 60 
Rosuvastatin 10 mg 
plus fenofibrate group  
n = 53
Placeboa then 
fenofibrate  
group  
n = 49 
TG 
  Baseline mmol/L (SD) 
  Mean percent change from baseline at 6 weeks (%) 
  Mean percent change from baseline at 24 weeks (%)
 
3.6 (1.0) 
4.7 
-30.3
 
3.5 (1.2) 
-24.5b 
-40.9
 
3.5 (1.3) 
-29.5b 
-47.1c
 
4.2 (1.8) 
4.7 
-33.6
LDL-C 
  Baseline mmol/L (SD) 
  Mean percent change from baseline at 6 weeks (%) 
  Mean percent change from baseline at 24 weeks (%)
 
3.7 (0.7) 
-0.6 
-46.7
 
3.9 (0.8) 
-40.7b 
-34.1d
 
3.9 (0.8) 
-45.8b 
-42.2
 
3.7 (0.8) 
-0.6 
0.7d
TC 
  Baseline mmol/L (SD) 
  Mean percent change from baseline at 6 weeks (%) 
  Mean percent change from baseline at 24 weeks (%)
 
6.2 (0.7) 
1.1 
-36.6
 
6.5 (0.8) 
-31.4b 
-31.0
 
6.4 (0.9) 
-36.6b 
-36.3
 
6.3 (0.9) 
1.1 
-7.5d
HDL-C 
  Baseline mmol/L (SD) 
  Mean percent change from baseline at 6 weeks (%) 
  Mean percent change from baseline at 24 weeks (%)
 
1.0 (0.2) 
1.2 
6.4
 
1.1 (0.2) 
9.9b 
10.8
 
1.0 (0.2) 
10.1b 
11.7
 
1.0 (0.2) 
1.2 
9.2
VLDL-C 
  Baseline mmol/L (SD) 
  Mean percent change from baseline at 6 weeks (%) 
  Mean percent change from baseline at 24 weeks (%)
 
1.7 (0.7) 
4.7 
-43.6
 
1.6 (0.6) 
-33.9b 
-46.8
 
1.4 (0.6) 
-34.9b 
-44.2
 
1.8 (0.9) 
4.7 
-30.1
LDL-C:HDL-C ratio 
  Baseline (SD) 
  Mean percent change from baseline at 6 weeks (%) 
  Mean percent change from baseline at 24 weeks (%)
 
3.8 (1.0) 
-2.0 
-48.9 
 
3.7 (0.8) 
-45.6b 
-38.8e
 
3.8 (0.9) 
-50.6b 
-46.8
 
3.9 (1.0) 
-2.0 
-6.3d
TC:HDL-C ratio 
  Baseline mmol/L (SD) 
  Mean percent change from baseline at 6 weeks (%) 
  Mean percent change from baseline at 24 weeks (%)
 
6.4 (1.4) 
0.5 
-39.2
 
6.2 (1.1) 
-36.5b 
-36.2
 
6.3 (1.2) 
-42.0b 
-41.9
 
6.7 (1.5) 
0.5 
-13.9d
Non-HDL-C:HDL-C ratio 
  Baseline mmol/L (SD) 
  Mean percent change from baseline at 6 weeks (%) 
  Mean percent change from baseline at 24 weeks (%)
 
5.4 (1.4) 
0.5 
-47.3
 
5.2 (1.1) 
-43.7b 
-43.5
 
5.3 (1.2) 
50.3b 
-50.4
 
5.7 (1.5) 
0.5 
-16.6d
ApoA-I 
  Baseline g/dL (SD) 
  Mean percent change from baseline at 6 weeks (%) 
  Mean percent change from baseline at 24 weeks (%)
 
139.4 (17.8) 
-1.4 
2.7 
 
144.8 (21.3) 
0.7 
4.7
 
141.1 (20.2) 
3.0f 
5.4
 
139.5 (22.8) 
-1.4 
5.0
ApoB 
  Baseline mg/dL (SD) 
  Mean percent change from baseline at 6 weeks (%) 
  Mean percent change from baseline at 24 weeks (%)
 
163.4 (29.0) 
-0.4 
-41.4
 
168.0 (21.3) 
-34.2b 
-35
 
164.4 (25.6) 
-38.9b 
-40.2
 
163.3 (28.0) 
-0.4 
-7.6d
ApoB: ApoA-I 
  Baseline (SD) 
  Mean percent change from baseline at 6 weeks (%) 
  Mean percent change from baseline at 24 weeks (%)
 
1.2 (0.3) 
1.6 
-41.9
 
1.2 (0.2) 
-33.5 
-37.2
 
1.1 (0.2) 
-39.8 
-42.7
 
1.2 (0.3) 
1.6 
-11.3d
Notes: aSix week data combined for two placebo groups; bP , 0.001 compared to placebo; cP = 0.001 compared to placebo/rosuvastatin 10/20/40 mg group; dP , 0.001 
compared to placebo/rosuvastatin 10/20/40 mg group; eP , 0.017 compared to placebo/rosuvastatin 10/20/40 mg group; fP , 0.0253 compared to placebo.
Abbreviations: TG, triglycerides; LDL-C, low density lipoprotein cholesterol; TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; vLDL-C, very-low density 
lipoprotein cholesterol; non-HDL-C, non-high-density lipoprotein-cholesterol; ApoA-1, apolipoprotein Ai; ApoB, apolipoprotein B.Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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plus fenofibrate groups were myalgia (3/115), creatine kinase 
(CK) greater than three times upper limits of normal (4/115), 
increased aspartate aminotransferase (AST) (6/115), and 
increased alanine aminotransferase (ALT) (6/115). None of 
these patients with AST/ALT elevations were symptomatic 
and all continued treatment. No subject had a clinically sig-
nificant increase in CK of greater than ten times upper limit 
of normal (ULN).
Studies evaluating the combination 
of rosuvastatin and fenofibric acid
The efficacy and safety of fenofibric acid (ABT-335) with low 
or moderate dose rosuvastatin was evaluated by Jones et al 
in a phase 3 multicenter, randomized, double-blind, active-
controlled trial.24 The study was designed with a 6-week 
washout period of lipid lowering medications   followed by 
a 12-week treatment period where patients were random-
ized to oral administration of fenofibric acid at 135 mg, 
fenofibric acid 135 mg with rosuvastatin 10 mg or 20 mg, 
or rosuvastatin alone at 10 mg, 20 mg or 40 mg. A 30-day 
safety period evaluation followed the 12-week treatment 
phase. Male and non-pregnant female patients at least 18 
years of age were included in the study that had mixed dys-
lipidemia (fasting TG $ 150 mg/dL, HDL-C , 40 mg/dL 
for men and ,50 mg/dL for women, LDL-C $ 130 mg/dL). 
Extensive inclusion and exclusion criteria were previously 
published.25 It was recommended that patients adhere to the 
American Heart Association diet.24 The screening TG level 
of #250 or .250 mg/dL along with diabetic status was part 
of the stratification for randomization. The mean percent 
change of HDL-C, TG, and LDL-C values from baseline 
were the primary efficacy endpoints. Additional secondary 
efficacy endpoints were non-HDL-C, VLDL-C, TC, ApoB, 
and high sensitivity C-reactive protein (hsCRP). Statistical 
comparisons were with fenofibric acid plus rosuvastatin 
compared to rosuvastatin alone for HDL-C, TG, and 
secondary endpoints. The statistical analyses of LDL-C and 
non-HDL-C changes were with a comparison of fenofibric 
acid plus rosuvastatin 10 or 20 mg vs fenofibrate alone. The 
primary and secondary efficacy endpoints are summarized in 
Table 5. The high dose rosuvastatin 40 mg was not evaluated 
for statistical significance due to low enrollment in this 
treatment group. The safety profile assessed specific adverse 
effects along with laboratory monitoring (Table 6). The most 
common adverse event was myalgia which was slightly 
lower in occurrence when fenofibric acid was combined with 
rosuvastatin. Creatine kinase elevation greater than 5 times 
the ULN was reported in 7 patients receiving fenofibric acid 
with rosuvastatin compared to 5 patients using rosuvastatin 
alone. No cases of rhabdomyolysis were documented. 
Elevation in ALT and AST greater than 3 times ULN was 
rare in occurrence.
Following the conclusion of the initial study by Jones et al 
subjects were eligible to enroll in a 52-week open label 
extension trial of fenofibric acid 135 mg with moderate dose 
rosuvastatin at 20 mg.26 Subjects who completed 2 other 
identically designed trials that utilized low to moderate 
doses of atorvastatin27 and simvastatin28 were also included 
in this 52-week open label follow-up trial, and continued 
their respective statin therapy. Published efficacy results in 
this 1-year follow-up trial did not separate the statin utilized; 
therefore reported efficacy results include a moderately 
dosed statin (simvastatin 40 mg, atorvastatin 40 mg or 
rosuvastatin 20 mg) plus fenofibric acid 135 mg.26 At 52 
weeks continued effects on TG, HDL-C, and LDL-C was 
observed. The incidence of treatment-related adverse effects 
when combining all fenofibric acid and statin groups was 
27.4% which led to discontinuation in 8.3% of patients. The 
combined treatment group adverse effects were CK . 5 times 
ULN (1.3%), ALT . 3 times ULN (1.2%), AST . 3 times 
ULN (0.5%), and serum creatinine $2 times baseline value 
(0.9%). Specific analysis of the rosuvastatin and fenofibric 
acid combination treatment arm showed a similar adverse 
effect profile as the combined statin groups plus fenofibric 
acid (Table 7). Of the 1186 patients receiving fenofibric acid 
and rosuvastatin, treatment-related adverse effects occurred 
in 27.7% (328/1186) which led to 8.3% discontinuing 
therapy. Adverse effects reported were CK . 5 times upper 
limits of normal (1.7%), ALT . 3 times upper limits of 
normal (1.2%), AST . 3 times upper limits of normal 
(0.4%), and serum creatinine $2 times baseline (0.6%). 
Treatment-related serious adverse events were reported in 
0.3% of subjects, but no treatment-related rhabdomyolysis 
or death was documented.
Following the completion of the 52-week trial by Bays et al 
subjects were eligible to enroll in a 52-week extension study 
(year 2) conducted by Kipnes et al.29 Subjects continued to take 
the same treatments as previously utilized in the initial 52-week 
trial by Bays et al. Of the 310 patients included in the year 2 
trial, 174 subjects received fenofibric acid 135 mg and rosuvas-
tatin 20 mg. A sustained effect on lipid efficacy variables was 
reported with this combination. Efficacy results were reported 
as the mean change at the end of the year 2 study as compared 
to baseline data at enrollment in one of the three initial tri-
als, which spread over 116 weeks (12-week trial +52 week 
trial +52 week trial). The mean percent changes from baseline 
to week 116 in TG, LDL-C, non-HDL-C, TC, VLDL-C, and 
HDL-C are reported in Table 8. The first occurrence of an Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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Fenofibrate or fenofibric acid with rosuvastatin
adverse effect was tracked over the study period. The majority 
of adverse effects occurred early in therapy. In the extension 
period, adverse effects reported were CK . 5 times ULN 
(2.3%, 4/174), ALT . 3 times ULN (1.1%, 2/174), AST . 3 
times ULN (0.6%, 1/174), and serum creatinine $2 times 
baseline (1.7%, 3/174). Two patients discontinued treatment 
due to myalgia; however no rhabdomyolysis or deaths were 
reported. The combined treatment group adverse effects were 
elevated CK (1.6%, 5/310), ALT (0.6%, 2/310), AST (0.3%, 
1/310), and serum creatinine (2.3%, 7/310). Further details 
on adverse effects are listed in Table 7.
Another phase III study, published as an abstract, with 
760 patients, evaluated the efficacy and safety of fenofibric 
acid with rosuvastatin in patients with mixed dyslipidemia 
(LDL-C $ 130 mg/dL, TG $ 150 mg/dL, HDL-C , 40 mg/dL 
males, , 50 mg/dL females).30 The 12-week study randomized 
individuals to fenofibric acid 135 mg/day, rosuvastatin 5 mg/
day or fenofibric acid 135 mg/day plus rosuvastatin 5 mg/
day. Statistically significant results, when comparing rosu-
vastatin to fenofibric acid with rosuvastatin, were a mean 
percent change from baseline of HDL-C (rosuvastatin 12.4%, 
combination 23.0%), TG (rosuvastatin -17.5%, combination 
-40.3%), VLDL-C (rosuvastatin -22.2%, combination 
-41.3%), ApoB (rosuvastatin -26.4%, combination -30.9%), 
TC (rosuvastatin -25%, combination -28.1%) and hsCRP 
(rosuvastatin -11.4%, combination -28%). The decrease 
in LDL-C reached statistical significance when comparing 
fenofibric acid to fenofibric acid with rosuvastatin (fenofibric 
acid -4.1%, combination -28.7%). The use of fenofibric acid 
with rosuvastatin was well tolerated.
Safety concerns with combination 
rosuvastatin and fenofibrate/
fenofibric acid therapy
Myopathy, hepatotoxicity and renal damage are possible 
adverse effects associated with the combination use of 
fibrates and statins.31 A database review further defining the 
risk, reports an approximate 15 times lower risk of rhab-
domyolysis when fenofibrate is used in combination with 
the currently available statins compared to gemfibrozil.32 
Although there are limitations to database reviews, which 
may under-report adverse events, the significant difference 
in event rates suggests that each fibrate is not the same in 
regards to statin interactions. Pharmacokinetic reasons for 
differences in toxicity associated with the combination of 
fenofibrate and statins has been previously discussed.
Due to reports of increased myopathy associated with the 
combination of fibrates and statins, prescribing information 
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of rosuvastatin, fenofibrate and fenofibric acid lists a warning 
when using these medications together.15–17 Specific clinical 
studies evaluating the use of rosuvastatin with fenofibric 
acid,24,26,29,30 or fenofibrate23 suggests that combination use 
is well tolerated and is as safe as therapy with the individual 
agents used as monotherapy. The majority of these   studies 
specifically evaluated fenofibric acid with concomitant 
  rosuvastatin therapy and data up to 2 years supports the safety 
of this combination.29 The use of fenofibrate may be equally 
safe to use since fenofibrate is rapidly metabolized to fenofibric 
acid and no pharmacokinetic interaction was identified when 
used with concomitant rosuvastatin therapy.21 However, formal 
long-term safety trials have not been conducted with the use 
of rosuvastatin and fenofibrate. Another potential concern is 
the lack of data regarding the use of high dose statin therapies 
with any form of fenofibrate.17,18 Therefore, practitioners 
should confirm safety with lower doses of rosuvastatin before 
progressing to rosuvastatin 40 mg when used in conjunction 
with either fenofibrate or fenofibric acid.
Although current study data reports no major problems 
with rosuvastatin and fenofibrate, safety concerns still may 
exist given the possibility of an additive toxicity as each of 
the individual agents have reports of myopathy and hepato-
toxicty.31 Individual case reports of possible toxicities with 
combination therapy have been published. A report by Ireland 
et al describes a 67-year-old patient with an elevated CK 
(13,808 U/L), and serum creatinine (3.6 mg/dL) following 
the addition of fenofibrate 160 mg to rosuvastatin therapy.33 
The patient was taking rosuvastatin 10 mg for 9 months with 
a recent dose increase to 20 mg. In this case it is   difficult to 
determine if the exact cause of rhabdomyolysis was due to the 
recently-increased rosuvastatin dose, addition of   fenofibrate 
or perhaps a combination of the two changes. A report by 
Dedhia et al describes a 68-year-old male with evidence of 
rhabdomyolysis following the addition of fenofibrate 160 mg 
daily to rosuvastatin 10 mg daily.34 After 3 weeks of taking 
both medications, he had symptoms of myopathy and renal 
failure with a CK level of 23,665 U/L and a serum creatinine 
of 2.3 mg/dL. Both therapies were stopped and the patient was 
treated with hydration. The patient   reportedly recovered and 
subsequently tolerated rosuvastatin and ezetimibe therapy.
Overall the risk of severe adverse effects with the 
  combination of rosuvastatin and fenofibrate is minimal. 
Table 8 Lipid outcomes in the Kipnes trial29
Fenofibric acid + 
rosuvastatin 20 mg
HDL-C n = 161 
  Baseline mean (mg/dL) 
  Final mean at 116 weeks (mg/dL) 
  Mean percent change from baseline (%) ± SD
 
38.3 
45.0 
19.2 ± 25.23
TG n = 161 
  Baseline mean (mg/dL) 
  Final mean at 116 weeks (mg/dL) 
  Mean percent change from baseline (%) ± SD
 
294.5 
137.5 
-48.2 ± 22.61
LDL-C n = 159 
  Baseline mean (mg/dL) 
  Final mean at 116 weeks (mg/dL) 
  Mean percent change from baseline (%) ± SD
 
152.5 
87.0 
-40.9 ± 20.66
Non-HDL-C n = 161 
  Baseline mean (mg/dL) 
  Final mean at 116 weeks (mg/dL) 
  Mean percent change from baseline (%) ± SD
 
222.6 
113.2 
-48.6 ± 13.58
VLDL-C n = 152 
  Baseline mean (mg/dL) 
  Final mean at 116 weeks (mg/dL) 
  Mean percent change from baseline (%) ± SD
 
71.4 
26.6 
-56.8 ± 25.17
Total-C n = 161 
  Baseline mean (mg/dL) 
  Final mean at 116 weeks (mg/dL) 
  Mean percent change from baseline (%) ± SD
 
260.9 
158.1 
-38.7 ± 12.16
Abbreviations:  HDL-C,  high-density  lipoprotein-cholesterol;  TG,  triglycerides; 
LDL-C, low-density lipoprotein-cholesterol; non-HDL-C, non high-density lipoprotein-
cholesterol; vLDL-C,  very-low  density  lipoprotein-cholesterol;  total-C,  total 
cholesterol.
Table 7 Adverse events in the Bays26 and Kipnes29 trials, n (%)
Fenofibric acid plus rosuvastatin  
20 mg at 52 weeks  
n = 1167
Fenofibric acid plus rosuvastatin 
20 mg at 116 weeks  
n = 174
CK . 5 times ULN 
CK . 10 times ULN 
Discontinuation due to increased CK 
Rhabdomyolysis
20 (1.7)  
6 (0.5) 
11 (0.9) 
0
4 (2.3) 
3 (1.7) 
1 (0.6) 
0
ALT . 3 times ULN on 2 consecutive visits 
AST . 3 times ULN on 2 consecutive visits 
Discontinuation due to increased ALT and/or AST
14 (1.2) 
5 (0.4) 
9 (0.8) 
2 (1.1) 
1 (0.6) 
1 (0.6)
Creatinine . 2 mg/dL 
Creatinine $ 2 × baseline 
Discontinuation due to increased creatinine
14 (1.2) 
7 (0.6) 
15 (1.3) 
3 (1.7) 
3 (1.7) 
0 
Abbreviations: CK, creatine kinase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limits of normal.Clinical Pharmacology: Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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However, given the rare case reports of myopathy and rhab-
domyolysis, patients should be cautioned to report any abnormal 
muscle pain. Patients should also be monitored for hepatotoxic-
ity with periodic monitoring of liver function tests.15–17 Although 
an increased risk of liver toxicity has not been reported with 
the combination, monitoring is   appropriate. In patients taking 
rosuvastatin, liver   function tests (LFTs) should be monitored 
prior to therapy and after 12 weeks of therapy.15 Additional 
testing should occur 12 weeks after any dose increase. If the 
LFTs are normal then monitoring may occur every six months. 
Patients with a history of renal insufficiency, heart failure, and 
severe debilitation should not use the combination of rosuvas-
tatin (or other statins) and fenofibrate as these conditions may 
make them more susceptible to adverse effects.35 Prescribing 
information also suggests a higher incidence of myopathy in 
patients with diabetes or hypothyroidism.17
Recommendation
The successful treatment of mixed dyslipidemia has proven to 
be very difficult due to the numerous lipid abnormalities that 
occur simultaneously. Therefore, in order to achieve the desired 
lipid goals, combination drug therapy is frequently needed. On 
the surface, implementing combination drug therapy appears 
to be a relatively easy and effective approach. However, 
combining lipid lowering agents is often associated with 
increased risks of developing medication adverse effects.
Concomitant statin and gemfibrozil therapy used to treat 
mixed dyslipidemia, has been associated with a significant 
increase in adverse effects such as myopathy and rhabdomy-
olysis. Fenofibrate and fenofibric acid are also primarily used 
to lower TG levels and used in combination with statin therapy 
to treat mixed dyslipidemia. Although the combination of 
statin therapy with fenofibrate or fenofibric acid therapy car-
ries a lower risk of increased adverse effects than gemfibrozil 
concern for potential increased adverse effects still exists.32
Based on a review of the available literature, combination 
therapy with rosuvastatin and fenofibrate or fenofibric acid 
appears to be effective. The Durrington study demonstrated 
that combination rosuvastatin and fenofibrate therapy in type 2 
diabetics resulted in significant reductions in TG and LDL-C 
levels along with an increase in HDL-C.23 The combination 
therapy was well-tolerated with minimal adverse effects.
The Jones trial assessed the use of various doses of rosu-
vastatin either alone or in combination with fenofibric acid.24 
The results from this study demonstrated that statistically 
significant changes were seen with combination therapy 
(rosuvastatin plus fenofibric acid) compared to rosuvastatin 
alone with TG lowering and elevations in HDL-C. The combi-
nation of rosuvastatin and fenofibric acid were well-tolerated 
in this study. A year-long extension of the Jones trial was 
then completed with rosuvastatin 20 mg with fenofibric acid 
135 mg.26 Similar to the first phase of this trial, the one-year 
follow-up demonstrated a continued effect on TG, LDL-C, 
and HDL-C with combination therapy. The   rosuvastatin and 
fenofibric acid combination was well tolerated and demon-
strated similar rates of adverse effects as other statin agents 
plus fenofibric acid. A second year phase of this trial was 
then completed comparing the same treatments in the one 
year follow-up trial.29 The results of the 2-year follow-up 
demonstrated a sustained benefit on lipid profiles, similar to 
what was seen in the 1-year follow-up phase.
Based on review of the literature, rosuvastatin can be 
safely and effectively combined with fenofibrate or fenofibric 
acid to treat mixed dyslipidemia. Studies demonstrated that 
this combination results in significant reductions in TG 
and LDL-C levels, and elevations in HDL-C. Dosing of 
rosuvastatin in the combination treatment groups involved 
low-moderate doses (5–20 mg per day). Rosuvastatin 
40 mg with concomitant fenofibrate or fenofibric acid has 
not been evaluated therefore caution should be utilized 
before prescribing this higher dose. Long-term studies 
with rosuvastatin and fenofibrate or fenofibric acid will be 
needed to determine if there is a benefit in clinical outcomes 
(mortality reduction) when treating mixed dyslipidemia. 
When this combination therapy is used, patients should be 
monitored closely for any potential adverse effects.
Conclusion
Treatment of mixed dyslipidemia is fraught with difficulty 
because of the need to reduce LDL-C and TG levels, while 
trying to elevate HDL-C levels. In order to succeed in doing 
this, combination drug therapy is often the only effective option. 
Unfortunately, the drug combinations utilized for mixed dyslipi-
demia potentially increase the risk for adverse events. Rosuvas-
tatin, the newest in its class, is the most potent statin currently 
available and provides significant reductions in LDL-C and 
TG and elevations in HDL-C. In addition, fenofibrate and 
fenofibric acid provides significant effects in lowering TG levels 
and raising HDL-C. When used in combination to treat mixed 
dyslipidemia, rosuvastatin and fenofibrate or fenofibric acid 
demonstrate beneficial effects in this patient population and is 
well tolerated with no greater risk of adverse events.
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